Reply to the letter to the editor 'Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?' by Abali et al

Ann Oncol. 2015 Jan;26(1):245-246. doi: 10.1093/annonc/mdu476. Epub 2014 Oct 14.

Authors

K Sugihara¹, M Yoshida², M Ishiguro³

Affiliations

¹ Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo. Electronic address: k-sugi.srg2@tmd.ac.jp.
² Cancer Chemotherapy Center, Osaka Medical College Hospital, Osaka.
³ Department of Translational Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.

PMID: 25316256
DOI: 10.1093/annonc/mdu476

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Colonic Neoplasms / drug therapy*
Colonic Neoplasms / mortality*
Drug Combinations
Female
Humans
Leucovorin / therapeutic use*
Male
Oxonic Acid / therapeutic use*
Tegafur / therapeutic use*
Uracil / therapeutic use

Substances

Drug Combinations
S 1 (combination)
Tegafur
Uracil
Oxonic Acid
Leucovorin

Supplementary concepts

1-UFT protocol